COMMUNIQUÉS West-GlobeNewswire

HealthTab™ Enters Multi-Year Collaboration Agreement with Abbott for Point-of-Care Testing Across the UK
20/08/2026
VANCOUVER, British Columbia, Aug. 20, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) is pleased to announce that its wholly-owned subsidiary, HealthTab Ltd, has entered into a formal collaboration agreement [...]
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement
20/08/2026
NANJING, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the full abstract of the Phase II clinical study evaluating [...]
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
20/08/2026
Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring BioNTech’s leadership in [...]
BioPorto announces Interim Results for the Second Quarter and First half of 2026
20/08/2026
August 20, 2026 Announcement no. 14 BioPorto announces Interim Results for the Second Quarter and First half of 2026 Copenhagen, Denmark, August 20, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or [...]
Vistin Pharma ASA: Second quarter and YTD 2026 financial results
20/08/2026
Oslo, Norway, 20 August 2026 Vistin Pharma ASA (VISTN) today announces its financial results for the second quarter and first half of 2026. Revenue in the second quarter amounted to MNOK 100, compared to MNOK 118 in Q2 [...]
ALK appoints Jacob Glenting as head of Global R&D
20/08/2026
ALK announces the appointment of Jacob Glenting as new Executive Vice President (EVP) and head of Global R&D, effective 1 September 2026. This position has been vacant since February 2026. Jacob Glenting is [...]
Six-month interim report (Q2) 2026 (unaudited)
20/08/2026
ALK delivers 18% organic revenue growth with operating profit (EBIT) up 19% in Q2 ALK sustained strong momentum in Q2, with double-digit growth across all regions driven by sales of tablets and anaphylaxis products. [...]
Zelluna ASA: Second Quarter 2026 results
20/08/2026
Oslo, 20 August 2026 – Zelluna (OSE: ZLNA), a clinical-stage company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents [...]
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement
20/08/2026
NANJING, China, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the full abstract of the Phase II clinical study evaluating [...]
Edesa Biotech Announces Pricing of $25.0 Million Public Offering
20/08/2026
TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno- [...]
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
20/08/2026
MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026. H1 2026 [...]
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
20/08/2026
Revenue for the first half of 2026 increased 29% year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. Expanded executive leadership with appointments of Dr. Faical [...]
Picard Medical Reports Second Quarter 2026 Financial Results
19/08/2026
- Revenue Increases 39% and Net Loss Decreases 16%- Year-to-Date Revenue Increases 50%, with ~$0.9 Million in Gross Profit TUCSON, Ariz., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“ [...]
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)
19/08/2026
GENGLYCOS is the first gene therapy approval, and fifth FDA approval overall, for the company Approval provides a long-awaited first-ever option to reduce the burden of care associated with GSDIa Ultragenyx received a [...]
Solésence Reports Second Quarter 2026 Financial Results
19/08/2026
Quarterly Report Filed on Form 10-Q Company to Host Conference Call at 5:00 p.m. ET Today ROMEOVILLE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically driven health care [...]
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
19/08/2026
REYKJAVIK, ICELAND (August 19, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients [...]
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
19/08/2026
REYKJAVIK, Iceland, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar [...]
Dr. Jacqueline Youtsos Expands Access to Dermatology and Medical Aesthetics with ReNu Medical & Spa in Parsons
19/08/2026
PARSONS, Kan., Aug. 19, 2026 (GLOBE NEWSWIRE) -- {{DATELINECITY_DATE_GLOBENEWSWIRE_BUG} ReNu Medical & Spa is proud to announce the opening of its newest location in Parsons, Kansas, expanding access to high-quality [...]
DNA X, Inc. Reports Second Quarter 2026 Financial Results
19/08/2026
- Strengthened balance sheet with $1.8 million cash from new convertible debt in Q2 and additional $5.0 million through the sale of preferred stock after quarter end -Converted $3.1 million outstanding note to preferred [...]

Pages